论文部分内容阅读
目的:分析乳腺癌患者血浆中血小板反应蛋白-1(TSP-1)的表达与乳腺癌临床病理特征及原发病灶分子指标之间的关系。方法:采集2009年7月~2010年12月在赣南医学院第一附属医院接受手术治疗的100例乳腺癌患者及50例乳腺良性疾病患者术前和术后血液标本以及临床病理资料,同时采集同期50例健康成年女性血液标本,分别采用ELISA方法测定以上标本血浆中TSP-1的表达水平。采用SPSS15.0统计软件包进行数据分析。结果:1乳腺癌患者血浆中TSP-1的表达明显高于乳腺良性疾病患者和健康成年女性(F=244.01,P<0.001)。2乳腺癌患者术后血浆中TSP-1的表达较术前明显减低(t=15.01,P<0.001)。3乳腺良性疾病患者术前、术后血浆中TSP-1的表达无统计学差异(t=0.019,P=0.985)。4乳腺癌患者血浆中TSP-1的表达与乳腺癌患者原发病灶的大小、腋窝淋巴结转移状况、TNM分期呈正相关,乳腺原位癌患者血浆中TSP-1的表达明显低于浸润性乳腺癌的表达。5乳腺癌患者血浆中TSP-1的表达与原发病灶ER、PR的表达呈正相关(P<0.001),与原发病灶Her-2的表达不相关(P>0.05)。结论:乳腺癌患者血浆中TSP-1的表达明显存在异常,在乳腺癌的发生和发展过程中,TSP-1可能是一个原癌基因,促进乳腺癌的发生和发展。检测乳腺癌患者血浆TSP-1的表达可能在乳腺癌的筛选、早期诊断、治疗、术后复发转移的监测等方面具有一定的临床价值。
OBJECTIVE: To analyze the relationship between the expression of thrombospondin-1 (TSP-1) and the clinicopathological features of breast cancer and the primary tumor molecular markers in patients with breast cancer. Methods: Preoperative and postoperative blood specimens and clinicopathological data were collected from 100 cases of breast cancer patients and 50 cases of benign breast diseases undergoing surgery in the First Affiliated Hospital of Gannan Medical College from July 2009 to December 2010. At the same time, Blood samples of 50 healthy adult women were collected at the same period, and the levels of TSP-1 in plasma were measured by ELISA. SPSS15.0 statistical software package for data analysis. Results: 1 The expression of TSP-1 in plasma of breast cancer patients was significantly higher than that of benign breast diseases and healthy adult women (F = 244.01, P <0.001). The expression of TSP-1 in plasma of patients with breast cancer was significantly lower than that before operation (t = 15.01, P <0.001). There was no significant difference in the expression of TSP-1 in preoperative and postoperative patients with benign breast diseases (t = 0.019, P = 0.985). The expression of TSP-1 in the plasma of breast cancer patients was positively correlated with the size of primary lesion, axillary lymph node metastasis and TNM stage in breast cancer patients. The expression of TSP-1 in plasma of breast cancer patients was significantly lower than that of invasive breast cancer expression. The expression of TSP-1 in the plasma of breast cancer patients was positively correlated with the expression of ER and PR (P <0.001), but not with the expression of Her-2 in primary breast cancer (P> 0.05). Conclusion: The expression of TSP-1 in plasma of patients with breast cancer is obviously abnormal. TSP-1 may be a proto-oncogene in the development and progression of breast cancer and promote the occurrence and development of breast cancer. Detection of plasma TSP-1 expression in breast cancer patients may have certain clinical value in screening, early diagnosis, treatment of breast cancer, monitoring of postoperative recurrence and metastasis.